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Abstract
Hyperactivity of the hypothalamic-pituitary-adrenal axis is a consistent biological characteristic of 
depression and response normalization coincides with clinical responsiveness to antidepressant 
medications. Desensitization of serotonin 1A receptor (5-HT1AR) signaling in the hypothalamic 
paraventricular nucleus (PVN) follows selective serotonin reuptake inhibitor (SSRI) 
antidepressant treatment and contributes to the antidepressant response. Estradiol alone produces a 
partial desensitization of 5-HT1AR signaling, and synergizes with SSRIs to result in a complete 
and more rapid desensitization than with SSRIs alone as measured by a decrease in the oxytocin 
and adrenocorticotrophic hormone(ACTH) responses to 5-HT1AR stimulation. G protein-coupled 
estrogen receptor1 (GPER1) is necessary for estradiol-induced desensitization of 5-HT1AR 
signaling, although the underlying mechanisms are still unclear. We now find that stimulation of 
GPER1 with the selective agonist G-1 and non-selective stimulation of estrogen receptors 
dramatically alter isoform expression of a key component of the 5-HT1AR signaling pathway, 
RGSz1, a GTPase activating protein selective for Gαz, the Gα subunit necessary for 5-HT1AR-
mediated hormone release. RGSz1 isoforms are differentially glycosylated, SUMOylated, and 
phosphorylated, and differentially distributed in subcellular organelles. High molecular weight 
RGSz1 is SUMOylated and glycosylated, localized to the detergent-resistant microdomain (DRM) 
of the cell membrane, and increased by estradiol and G-1 treatment. Because activated Gαz also 
localizes to the DRM, increased DRM-localized RGSz1 by estradiol and G-1could reduce Gαz 
activity, functionally uncoupling 5-HT1AR signaling. Peripheral G-1 treatment produced partial 
reduction in oxytocin and ACTH responses to 5-HT1AR-stimulation similar to direct injections 
into the PVN. Together, these results identify GPER1 and RGSz1 as novel targets for the 
treatment of depression.
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Introduction
The most consistent biomarker in depressed patients is increased hypothalamic-pituitary-
adrenal (HPA) axis activity, such as high levels of plasma corticotropin releasing hormone 
(CRH), adrenocorticotrophic hormone (ACTH), and cortisol [1; 2], and successful 
antidepressant treatment is frequently correlated with normalization of HPA axis activity 
[3]. Serotonin is a major mediator of the HPA axis [4]; recent studies have shown that 
depression-like behavior in rodents is modulated by serotonin receptors, in particular the 
serotonin 1A receptor (5-HT1AR) [5; 6].
Selective stimulation of 5-HT1AR with (+)8-OH-DPAT produces an increase in the plasma 
levels of oxytocin (OT), ACTH, and corticosterone, which can be prevented by treatment 
with the 5-HT1AR antagonist WAY 100 635 in the paraventricular nucleus of the 
hypothalamus (PVN)[7; 8]. Chronic treatment with SSRIs produces desensitization of 5-
HT1AR signaling in the PVN, as measured by a reduction in the OT and ACTH response to 
5-HT1AR stimulation [9; 10; 11]. It takes 3–12 weeks to achieve clinical efficacy with 
SSRIs [12; 13]. Since this therapeutic delay is thought to be partly due to the time it takes 
for desensitization of 5-HT1AR signaling in the PVN and contribute to normalization of the 
HPA axis, treatment that reduces the time to achieve desensitization could have tremendous 
therapeutic benefits [9; 14; 15; 16].
Neuroendocrine challenge tests that detect peripheral changes in hormone responses to 5-
HT1AR agonists can be used to measure desensitization of 5-HT1AR signaling in the PVN 
[8; 17]. We found that two-day estradiol treatment accelerates SSRI-induced 5-HT1AR 
desensitization [18]; however, the mechanism underlying this effect is still unclear. Minimal 
estrogen receptor (ER) α is expressed in the PVN, though it is abundant in the peri-PVN 
region [19]. ERβ is abundantly expressed in the PVN and importantly in OT expressing 
neurons and a subset of CRH expressing neurons [20; 21] but does not contribute to the 
desensitization of 5-HT1AR signaling in the PVN, as selective stimulation of ERβ does not 
produce the desensitization response and knocking down ERβ in the PVN does not prevent 
the desensitization response [22].
Several G protein-coupled ERs have been reported. A Gαq-coupled receptor is expressed in 
the arcuate nucleus of the hypothalamus, CA1 region of the hippocampus and primary 
cortical cells in culture but not in the PVN [23]. G protein-coupled estrogen receptor 1 
(GPER1, also known as GPR30) distribution in the brain is distinct from ERα or ERβ [24], 
and colocalizes with 5-HT1AR, OT, and CRH in the PVN [24; 25; 26; 27], demonstrating 
that GPER1 is positioned to play a role in the estradiol-modulated release of these 
hormones. Although the roles of ERα and the Gαq-coupled membrane estrogen receptor in 
the estradiol-induced desensitization response have not been directly tested, the selective 
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GPER1 agonist G-1 is sufficient to produce the desensitization of 5-HT1AR signaling and 
knocking down GPER1 prevents estradiol-induced desensitization [27; 28].
Nonetheless, the mechanisms by which GPER1 signaling alter 5-HT1AR signaling 
components to produce desensitization are still unclear. The release of OT and ACTH via 5-
HT1AR is dependent only on Gαz, not other members of the Gαi/o family [29]. However, 
Gαz protein levels in the membrane fraction [30] and total tissue homogenates of the PVN 
[28] are not altered by estradiol treatment. Gαz is active in the GTP-bound form and has a 
very slow intrinsic rate of GTP hydrolysis. RGSz1, a regulator of G protein signaling (RGS) 
protein, has a high affinity for Gαz and increases the rate of GTP hydrolysis by over 400-
fold, effectively down-regulating Gαz downstream signaling [31; 32]. By this mechanism, 
increased RGSz1 could cause desensitization of 5-HT1AR signaling. Indeed, our previous 
studies have shown that RGSz1 is up-regulated by estradiol and could thereby play an 
important role in the desensitization of 5-HT1AR signaling [28; 33]. Two-day estradiol 
treatment increases RGSz1 mRNA, and several RGSz1 protein isoforms in the PVN, 
including a 29kd protein measured in the membrane fraction [33] and 45 and 55kd proteins 
measured in total homogenates of the PVN [28].
RGSz1 in the rat has a predicted molecular weight of 27kD based on its amino acid 
sequence [34]; however, multiple isoforms exist in the brain. RGSz1 has been shown to 
undergo posttranslational modification in isolated mouse synaptosomal membranes, 
including glycosylation, SUMOylation, and phosphorylation [35; 36], which may affect its 
subcellular localization and ability to regulate Gαz and thus contribute to desensitization of 
5-HT1AR signaling. This study is a comprehensive investigation of the effects of ER 
stimulation on post-translational modifications to RGSz1 protein isoforms. We focus on the 
subcellular localization of the various isoforms, especially the detergent-resistant 
microdomains (DRM) of the plasma membrane, where active Gαz and 5-HT1AR are 




Female ovariectomized (OVX) Sprague-Dawley rats (225–250g) purchased from Harlan 
(Haslett, MI) were housed two per cage in a temperature-, humidity-, and light-controlled 
room (12 h light/dark cycle). Food and water were available ad libitum. All procedures were 
conducted in accordance with the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals and as approved by the University of Kansas Institutional Animal 
Care and Use Committee. All efforts were made to minimize animal discomfort and to 
reduce the number of animals used.
Drugs
17β-Estradiol-3-benzoate (EB) (Sigma-Aldrich, St. Louis, MO) was dissolved in 100% 
ethanol to a concentration of 25µg/ml and diluted to the final concentration with sesame oil. 
EB solution and sesame oil were administered at 0.4ml/kg. G-1 (1-(4-(6-
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ethanone), EMD Chemicals, Newark, NJ) was dissolved in 100% DMSO to a concentration 
of 5mg/ml and 10mg/ml and administered at 0.5ml/kg. (+)8-Hydroxy-2-
dipropylaminotetralin ((+)8-OH-DPAT, Tocris, Ellisville, MO). (+)8-OH-DPAT was 
dissolved in 0.85% NaCl (saline) at a concentration of 0.2mg/ml and administered at a dose 
of 0.2mg/kg. Solutions were made fresh before injection.
Experimental Procedure
Animals were randomly grouped according to the following complete block design: vehicle/
saline (n = 7), vehicle/DPAT (n = 8), EB/saline (n = 7), EB/DPAT (n = 8), G-1(2.5 mg/kg)/
saline (n = 7), G-1(2.5 mg/kg)/DPAT (n = 8), G-1(5 mg/kg)/saline (n = 7), G-1(5 mg/kg)/
DPAT (n = 8). Five days after OVX, rats were treated s.c. with EB (10µg/kg/day), G-1 (2.5 
or 5 mg/kg/day), or vehicle (DMSO) once a day for 2 days. Eighteen hours after the last 
treatment, rats were injected with (+)8-OH-DPAT (0.2mg/kg, s.c) or saline and sacrificed 
via decapitation 15 minutes later. The EB dosing regimen was based on our previous time 
course and dose-response studies demonstrating that 10ug/kg/day of EB for two days 
produces the maximal desensitization of 5-HT1AR signaling [28; 30]. At the time of 
experimental design, very little had been published regarding the systemic delivery of G-1 in 
rats; therefore, G-1 dose was calculated based on literature using implanted G-1 pellets in 
mice [37] and is similar to that used by Kastenberger et al., [38]. The 15 minute time period 
for sampling serum after 8-OH-DPAT was also based on a previous time course experiment 
which demonstrated that 15 minutes is the maximal response time for the effects of estradiol 
on ACTH and oxytocin [39]. Brains were removed and snap-frozen in dry-ice-cooled 
isopentane and then on dry ice. Trunk blood was collected in tubes containing 0.5ml 3M 
EDTA (pH 7.4). Brains and plasma were stored at −80°C until use.
Immunoblot assays
PVN was punched out from 300 µm-thick sections and tissue was homogenized as described 
previously [28]. Subcellular fractionation and isolation of the DRM from cortical tissue was 
performed as described previously [18]. Protein (10µg/lane) was resolved on a 12% SDS-
PAGE gel followed by transfer to polyvinylidene fluoride (PVDF) membrane. The 
membranes were incubated in blocking buffer and probed overnight using the following 
primary antibodies: goat anti-SUMO2/3 1:200 (#sc-5231, Santa Cruz Biotechnology, Dallas, 
TX), mouse anti-phospho(Ser/Thr/Tyr) 1:100 (#E3074, Spring Biosciences, Pleasanton, 
CA), mouse anti-flotillin-1 1:2000 (#610820, BD Biosciences, San Jose, CA), mouse anti-
Na+/K+ATPase α1 1:2000 (#sc-21712, Santa Cruz Biotechnology), rabbit anti-calreticulin 
1:2000 (#Ab4, Abcam, Cambridge, MA), goat anti-EEA1 (C-15) 1:1000 (#sc-6414, Santa 
Cruz Biotechnology), mouse anti-βactin (C4) 1:20,000 (#69100, MP Biomedicals, Solon, 
OH). Samples to be probed with the RGSz1 antibody were prepared without β-
mercaptoethanol to reduce background. RGSz1 antiserum was raised in rabbits against the 
last 15 amino acids of the C-terminal of RGSz1 by Biosynthesis (Lewisville, Texas). This 
RGSz1 antibody was previously shown to recognize a 27kD protein band in HEK293 cells 
transformed to over-express RGSz1but not in mock transformed cells [28]. Furthermore, the 
affinity purified RGSz1 antibody detected multiple protein bands at approximately the same 
molecular mass as in the current study, namely 27kD, 80kD, 90kD, 135kD and 145kD using 
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from 1.0 to 37 ng/lane of purified RGSz1 protein on a western blot. Detection of each of 
these bands was blocked by preadsorption of the RGSz1 antibody with purified RGSz1 
protein [33]. In the current study the RGSz1 antibody was affinity purified and used at a 
dilution of 1:100. After washing, membranes were incubated with the appropriate secondary 
antibody conjugated with horseradish peroxidase at a dilution of 1:10,000. Bands were 
detected with ECL substrate solution (GE Healthcare Biosciences, Piscataway, NJ) using 
BioRad ChemiDoc XRS+ molecular imager (BioRad, Hercules, CA). Bands were analyzed 
densitometrically using ImageLab software (BioRad, Hercules, CA). Each band was 
normalized to actin and calculated as percent of the control group within each blot. All 
samples were run in triplicate and the average for each was used for the final quantification.
Glycoprotein isolation
Glycoproteins from the membrane fraction of rat cortex were isolated via binding to a 
column containing WGA resin using a Pierce glycoprotein isolation kit (Thermo Scientific 
Inc). Glycoproteins were eluted from the column using the provided elution buffer or by 
heating at 95°C in 200µl SDS-PAGE sample buffer for 5 minutes. Glycoproteins were 
examined on immunoblots probed with affinity-purified anti-RGSz1 (1:100).
Immunoprecipitation
Membrane and cytosol fractions of the cortex containing 500–1000 µg of protein were pre-
cleared with 25 µl pre-washed protein G agarose beads (Invitrogen Carlsbad, CA) in total 
volume of 500 µl of IP buffer (50 mM Tris, pH 7.4, 10 mM EGTA, 100 mM NaCl, 0.5% 
Triton X-100, 20 mM NEM 1:100 protease inhibitor cocktail and 1:100 phosphatase 
inhibitor cocktail I and III) with rotation at 4°C for 1h. After centrifugation at 3000× g at 
4°C for 5 min, the supernatant was incubated with primary antibody (4µg mouse anti-
SUMO-1 (D-11), #sc-5308, Santa Cruz Biotechnology; 1:50 rabbit anti-RGSz1 or 4µg IgG 
control) and rotated at 4°C overnight. Pre-washed protein G beads (50 – 100 µl) were added 
to each tube and rotated at 4°C for 2 h. Protein G beads were pelleted by centrifugation at 
1000× g, at 4°C for 3 min and then resuspended in 0.5 ml ice cold IP buffer. After washing, 
the protein complexes were eluted in 25 µl 2X sample buffer without β-mercaptoethanol by 
heating at 95°C for 5 min, then centrifuging at 3000×g for 5 min. The supernatant was 
collected and stored at −80°C until used for immunoblotting.
Radioimmunoassay of plasma oxytocin and ACTH
Plasma oxytocin and ACTH were determined by radioimmunoassay as previously described 
with minor modifications [17]. Radioactive 125I oxytocin and 125I ACTH (specific activity 
of each: 2200 Ci/mmol) were obtained from Perkin Elmer (Waltham, MA) and DiaSorin 
(Stillwater, MN), respectively. Intra-assay coefficients of variation were 3.93 for the 
oxytocin assay and 2.17 for the ACTH assay.
Statistical analysis
All experiments were performed in triplicate and data are expressed as means ± SEM. One- 
or two-way analysis of variance (ANOVA) and Student-Newman-Keuls post hoc tests were 
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conducted using a statistical program (Statview version 5.0 software, SAS Institute Inc., 
Cary, NC).
Results
RGSz1 isoforms have selective subcellular localization
The predicted molecular weight of RGSz1 is 27 kD; however, previous studies from our 
laboratory and others have demonstrated multiple RGSz1 bands on western blots [28; 33; 
35; 36]. Western blotting with an affinity-purified RGSz1 antibody reveals a series of bands 
with differential distribution in the cytosol and membrane fractions in the cortex, 
hippocampus, hypothalamus and midbrain. Similar patterns of RGSz1 bands were seen in 
these brain regions but the relative abundance of individual RGSz1 isoforms varied.
To understand the functional importance of the different RGSz1 isoforms, we examined 
their subcellular localization via gradient centrifugation to separate the subcellular 
organelles based on their density (Figure 2A). The 135kD isoform colocalized with Na+/K
+ATPase, a plasma membrane marker. Interestingly, while the 90kD and 50kD bands did 
not completely co-localize with any marker tested in the present study, they did localize with 
each other and showed some overlap with the plasma membrane marker (Figure 2B). The 
80kD and 35kD bands were located in the early endosome, as marked by EEA1 (Figure 2C); 
however, as the fractions containing the early endosome also contain cytosolic markers [18], 
these isoforms could be located in the cytosol as well. Finally, the 45kD and 40kD bands 
were predominantly located in the ER, as determined by colocalization with calreticulin 
(Figure 2D).
Because activated Gαz proteins are localized in DRM of the plasma membrane [18], the 
RGSz1 isoform that facilitates GTP-Gαz hydrolysis would need to be located in the DRM. 
To this end, we isolated DRM with Triton X-100 treatment followed by sucrose gradient 
centrifugation. DRM fractions were identified by flotillin 1 (Figure 3A). Interestingly, the 
135kD (Figure 3B) and 90kD (Figure 3C) proteins both distributed in two distinct 
populations: one was located in the DRM as marked by flotillin 1, and another one was 
located outside the DRM. The 50kD RGSz1 isoform localized entirely in the DRM (Figure 
3C), while the 80kD band and the vast majority of the 40/45kD (unresolved) bands were not 
colocalized with the DRM, consistent with their location outside the plasma membrane 
(Figure 2).
Post-translational modification of RGSz1
To determine whether the increased molecular weights of the different RGSz1 isoforms 
could be due to post-translational modifications, we first used computer-assisted analysis of 
the RGSz1 amino acid sequence to predict potential modification sites. We found two 
possible sites for N-linked glycosylation (Center for Biological Sequence Analysis, http://
www.cbs.dtu.dk/services/NetOGlyc/), as well as potential phosphorylation sites on several 
serine, threonine, and tyrosine residues (Center for Biological Sequence Analysis, http://
www.cbs.dtu.dk/services/NetPhos/). In addition, we identified one SUMO consensus site via 
SUMOsp2.0 GPS program (http://sumosp.biocuckoo.org) (Figure 4A).
McAllister et al. Page 6













To examine glycosylation of RGSz1, glycoproteins from the membrane fraction of the 
cortex were isolated via binding to a column containing WGA resin, then eluted from the 
column using elution buffer. This procedure identified the 135kD band as the major 
glycosylated isoform of RGSz1 (Figure 4B); however, the yield was very low. Boiling the 
sample in SDS-PAGE buffer increased the amount of glycoproteins released from the WGA 
resin, and allowed us to detect significant bands at 135kD, 80kD, and 40kD, as well as 
several others (Figure 4C), suggesting that there are three major glycosylated RGSz1 protein 
isoforms. The lower intensity bands are likely either glycosylation of less abundant isoforms 
or represent degradation products.
We identified SUMOylated RGSz1using immunoprecipitation (IP) with SUMO 1 antibody 
followed by immunoblotting with the RGSz1 antibody. In the cytosol fraction, three bands 
were detected at 90kD, 50kD, and 45kD. In the membrane fraction, a 135kD band was 
detected, as well as a major band at 90 and 40kD (Figure 4D).
Next, anti-RGSz1 antibody was used to IP RGSz1 proteins from cytosol and membrane 
fractions of rat cortical tissue. Immunoblotting with anti-SUMO2/3 revealed a ladder of 
bands, with the clearest being at 35kD and 45kD in the membrane fractions and possibly the 
135kD RGSz1 isoform (Figure 4F). Immunoblotting with an antibody against serine/
threonine/tyrosine phosphorylation detected a strong band at 35kD and a lighter band at 
40kD in both the cytosol and membrane fractions after RGSz1 IP (Figure 4E).
GPER1 stimulation alters RGSz1 isoforms in the PVN
To test the hypothesis that alterations in RGSz1 expression and post-translational 
modification after GPER1 stimulation underlie estradiol-induced desensitization of 5-
HT1AR signaling, we first examined the effect of 5 mg/kg G-1 and EB treatment on the 
expression of the different RGSz1 isoforms in the PVN.
In the cytosol fraction of the PVN, both G-1 and EB treatment had dramatic effects on 
RGSz1 expression (Figure 5A and B). Both pretreatments increased expression of the 80kD 
(F(2,15) = 28, p < .0001) and 50kD bands (F(2,17) = 5.3, p = .017) and decreased expression 
of the 135kD (F(2,20) = 7.7, p = .0033) and 40/45kD bands (F(2,17) = 20, p < .0001), with no 
change in the 35kD (F(2,17) = 1.2, p = .29) relative to control. G-1 pretreatment increased 
expression of the 90kD band relative to both vehicle and EB (F(2,17) = 12, p = .0006). (+)8-
OH-DPAT had no effect on any of the RGSz1 isoforms (Figure 5C). Because the 
unmodified 29kD RGSz1 band is in such low abundance relative to the other isoforms, it is 
not easily detected with the affinity-purified antibody and thus was not measured in these 
experiments.
Interestingly, a 145 kD band is present in the PVN membrane but not detected in the other 
brain regions examined including the whole hypothalamus (Figure 5D). In the membrane 
fraction of the PVN, the predominant bands were at 145kD and 40/45kD (Figure 5E). 
However, due to the abundance of the band running at approximately 40kD, this band could 
also include the 45kD isoform. G-1 treatment produced a robust increase in the 145kD band 
(F(2,15) = 4.4, p =.03), while EB treatment had no effect relative to control (Figure 5F). The 
135kD band in the PVN was expressed in low abundance compared to the cytosol and other 
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brain regions, but was still quantifiable. Interestingly, both EB and G-1 treatment increased 
the 135kD isoform (F(2,14) = 6.1, p = .01) and decreased the 80kD isoform (F(2,16) = 28, p <.
0001). These results correspond to the changes in the cytosol, in which EB and G-1 
treatment had the opposite effect on the 135kD and 80kD isoforms. The abundance of the 
40kD band was not affected by treatment with EB or G-1 (F(2,14) = .25, p = .79). As in the 
cytosol, (+)8-OH-DPAT challenge had no effect on any of the RGSz1 protein isoforms 
(Figure 5G).
Peripheral G-1 administration reduces the hormone response to 5-HT1AR stimulation
Baseline levels of plasma OT were unchanged in the treatment groups compared to vehicle 
(Figure 6A). Activation of 5-HT1AR by (+)8-OH-DPAT increased plasma OT levels in 
vehicle-treated rats. The OT response was significantly reduced in the EB-treated group. 
The high dose of G-1 (5 mg/kg) significantly reduced the OT response comparable to EB; 
the low dose of G-1 (2.5 mg/kg) also reduced the OT response, although the effect was not 
as robust (two-way ANOVA: main effect of (+)8-OH-DPAT: F(1,37) = 493.6, p <.0001; 
main effect of pretreatment: F(3,37) = 8.541, p = .0002; interaction between pretreatment and 
challenge: F(3,37) = 5.840, p = .0023).
ACTH baseline response was not affected by any pretreatment (Figure 6B). Stimulation of 
5-HT1AR by (+)8-OH-DPAT increased ACTH levels in vehicle-treated rats. The magnitude 
of the ACTH response to (+)8-OH-DPAT was significantly reduced in EB-treated rats. Both 
doses of G-1 reduced ACTH significantly compared to vehicle and EB (two-way ANOVA: 
main effect of (+)8-OH-DPAT: F(1,44) = 842.6, p <.0001; main effect of pretreatment: F(3,44) 
= 7.707, p = .0003; interaction between pretreatment and challenge: F(3,44) = 7.180, p = .
0005). Together, these data demonstrate that peripheral injection of G-1 is sufficient to 
reduce the 5-HT1AR-mediated release of ACTH and oxytocin, similar to EB.
Discussion
The purpose of the present study was to identify RGSz1 isoforms that are positioned to alter 
5-HT1AR/Gαz signaling and determine if estradiol and specifically signaling through 
GPER1 impacts these RGSz1 isoforms. Our data suggest that the G-1-induced increases in 
the 135kD and perhaps the 145kD RGSz1 protein isoforms are a possible mechanism 
contributing to the desensitization of 5-HT1AR signaling. This hypothesis is based on the 
findings that the 135kD RGSz1 protein isoform is located in the DRM where it is positioned 
to attenuate 5-HT1AR/Gαz signaling and that stimulation of GPER1 by both estradiol and 
G-1 increased the levels of the 135kD RGSz1 protein isoform in the PVN. Although we 
identified three RGSz1 protein bands in the DRM migrating at approximately 135kD, 90kD 
and 50kD on immunoblots only the 135kD isoform was altered with EB and GPER1 
stimulation. Interestingly, we found that while EB and G-1 treatment produced comparable 
changes in most of the RGSz1 bands measured, only G-1 increased a 145kD band in the 
membrane, resulting in a dramatic increase relative to control and EB treatment. That this 
expression was so markedly affected by G-1 treatment and not EB suggests that this isoform 
could contribute to the apparent sensitivity of the ACTH response to G-1 over EB treatment. 
ACTH release is under the control of CRH, and while the mechanism by which Gαz 
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mediates CRH release is still unclear, it could be particularly susceptible to regulation by the 
145kD RGSz1 isoform. The 145kD band appears to be specific to the membrane fraction of 
the PVN; it is not seen in the cortex, hippocampus, amygdala, or even the other regions of 
the hypothalamus. The PVN does not contain enough protein to perform 
immunoprecipitation of RGSz1, so characterization of this isoform is difficult; however, its 
localization to the membrane fraction suggests that it could be localized to the DRM.
It is clear from the present study that signaling through GPER1 produces dramatic changes 
in posttranslational modifications of RGSz1 in the PVN. Except for the expression of the 
145kD RGSz1 isoform which was only detected in the PVN, the expression of the other 
RGSz1 isoforms is more similar among the brain regions examined, albeit with some 
isoforms being more highly expressed than others. However, changes in RGSz1 protein after 
EB or G-1 treatment are dramatically different depending on the brain region. Previous work 
in our laboratory found that EB treatment produced a decrease in the 40kD RGSz1 isoform 
in the hippocampus but no change in the amygdala. Furthermore, a decrease of the 40kD 
band was observed in the PVN after EB treatment but this band was increased in the rest of 
the hypothalamus [30]. In contrast to our findings in the PVN, the effects EB and G-1 on 
RGSz1 in the frontal cortex are subtle and largely non-significant (data not shown). These 
results suggest that regulation of RGSz1 posttranslational modification is under local 
control, most likely due to the relative levels of specific types of ER expressed in each 
region.
Investigation of RGSz1 posttranslational modifications identified SUMOylation, 
glycosylation, and phosphorylation of RGSz1 isoforms. The present study demonstrated that 
the 135kD, 90kD, and 50kD RGSz1 isoforms are SUMOylated with SUMO1 and are the 
only isoforms located in the DRM. Remarkably, our previous studies demonstrated that 
SUMOylation of both 5-HT1AR in the DRM and the 35kD Gαz isoform located in the DRM 
[18; 40]. Furthermore, treatment with EB and G-1 resulted in an increase in the 135kD 
RGSz1 in the membrane, with a corresponding decrease in the non-SUMOylated 80kD 
isoform in the cytosol. SUMOylation affects a variety of cellular processes including 
subcellular localization and control of protein-protein interactions. Vertebrates express three 
SUMO isoforms SUMO1, SUMO2 and SUMO3; SUMO2 and 3 are nearly identical and are 
referred to in combination as SUMO2/3. SUMO2/3 contains a SUMO consensus sequence, 
and can form poly-SUMO chains via isopeptide linkages; SUMO1 does not contain a 
consensus site and SUMOylation of a poly-SUMO chain with SUMO1 can thus serve to 
terminate the chain [41; 42]. We observed a ladder pattern of SUMO2/3 immunoreactivity 
after RGSz1 IP, which suggests chains of SUMO2/3. Addition of a SUMO1 molecule as a 
cap to a poly-SUMO2/3 chain could account for the increase in apparent molecular weight 
from 80kD to 135kD; thus SUMOylation may be acting as a molecular switch to increase 
RGSz1 in the DRM of the plasma membrane to regulate Gαz signaling. Since the DRM is 
the location of active GPCR signaling proteins, the increase in RGSz1 in the DRM would 
reduce the activity of Gαz signaling by hydrolyzing the activated GTP-bound Gαz to 
inactive GDP-bound Gαz. Our previous studies demonstrated that the 35kD Gαz isoform 
located in the DRM is decreased by EB treatment [18], and that 5-HT1AR is also localized to 
the DRM [40]. The EB and G-1 induced increase of DRM-localized RGSz1 together with 
the EB-induced decrease of DRM-localized Gαz would reduce 5-HT1AR signaling. Further 
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studies will be required to verify this putative mechanism. However, taken together with our 
previous studies [18; 40], our results suggest that SUMOylation with SUMO1 regulates key 
components of 5-HT1AR signaling pathway in the PVN which regulates hormone release, 
including 5-HT1AR, Gαz and RGSz1.
We found that the 35kD, and possibly the 50kD, RGSz1 isoforms are phosphorylated. 
Phosphorylation is critical in the control of many cellular pathways, and may be a regulator 
of non-nuclear SUMOylation as well [42]. Depending on the substrate, the negative charge 
of a phosphate group can enhance or inhibit SUMOylation [43; 44]. There is a serine residue 
(S159) adjacent to the SUMO consensus site that, if phosphorylated, could facilitate 
SUMOylation.
Protein glycosylation plays an important role in protein structure, signal transduction, cell-
cell interactions, and hormone action [45; 46; 47]. Addition and editing of carbohydrate 
units to proteins occurs in the endoplasmic reticulum and Golgi apparatus. Here, we found 
that a major glycosylated form of RGSz1, at 40kD, localized to the endoplasmic reticulum. 
The RGSz1 proteins of greater molecular weights than 40kD are also glycosylated, 
suggesting that the 40kD band, which is the most abundant of the RGSz1 isoforms, may 
serve as a pool from which, once glycosylated, other modifications such as SUMOylation 
can be added or removed, thus regulating RGSz1 localization and function [48].
Recent studies in the mouse have demonstrated a similar RGSz1 immunoblot profile in the 
mouse brain, including high molecular weight bands (130–150kD) that were glycosylated 
[35] and mid-range molecular weight bands that were SUMOylated and phosphorylated 
[36]. These results cannot be compared directly with this present study, as the studies were 
conducted in different species (there is 86% homology between mouse and rat RGSz1), 
different receptor signaling systems were examined, and the antibodies used to detect 
RGSz1 were raised differently. However, the results from the current study are consistent 
with those from the mouse studies demonstrating that post-translational modifications 
including SUMOylation, glycosylation and phosphorylation of RGSz1 result in numerous 
protein bands detectable on western blots.
The long-term goal of the present study is to identify novel targets to more rapidly produce 
desensitization of 5-HT1AR signaling in the PVN to improve the therapeutic effects of 
SSRIs [9; 15]. Two days of EB treatment produces a partial desensitization of 5-HT1AR 
signaling and synergizes with fluoxetine to produce a rapid and complete desensitization 
[18]. This effect is mediated by GPER1, as knockdown of GPER1 expression prevents EB-
induced desensitization, and intra-PVN injection of G-1 produces a partial desensitization of 
5-HT1AR signaling in the PVN [27; 28]. In the present study, we demonstrated that systemic 
G-1 treatment produces similar effects: first, a dose-dependent effect on OT release, with the 
higher dose reducing OT release by the same magnitude as EB. Second, both doses of G-1 
produced a similar reduction of plasma ACTH which was even more robust than EB 
treatment consistent with our previous intra- PVN results [27].
Increasing the dose of EB or extending the length of treatment does not further reduce the 
hormone response to (+)8-OH-DPAT [18; 30]. EB, as a physiologically active estrogen, 
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activates all ER with slightly higher selectivity for the nuclear ERs over GPER1 (Ki of EB 
for ERα, ERβ, and GPER1 is 0.30 nM, 0.38nM, and 5.7 nM, respectively) [49]. ERβ is 
abundantly expressed in OT- and subset of CRH-expressing neurons in the PVN, while ERα 
is abundant in GABAergic neurons of the peri-PVN region [19; 20; 21]; EB treatment 
therefore stimulates ER with potentially opposing effects that may diminish the GPER1 
response. G-1, on the other hand, is highly selective for GPER1 over ERα and ERβ (Ki for 
G-1 at GPER1 is 11 nM, with no significant binding at ERα or ERβ at concentrations up to 
1 µM) [49]. Additionally, there is a partial estrogen response element in the promoter region 
of the CRH gene, and estradiol treatment has been shown to increase CRH mRNA and 
protein expression, as well as AVP mRNA, likely through an ERβ-mediated mechanism 
[50]. Selective stimulation of GPER1 with G-1 avoids an ERβ-mediated EB-induced 
increase in CRH, thus blunting the ACTH response. The selectivity of G-1 for GPER1 over 
the nuclear ERs may also explain the differential changes in RGSz1 isoform between G-1 
and EB treatment.
In conclusion, the present results demonstrate that RGSz1 isoforms with different post-
translational modifications are differentially distributed in subcellular organelle. In 
particular, we identified a SUMOylated 135kD RGSz1 isoform in the DRM where it can 
physically interact with activated Gαz and shut off 5-HT1AR downstream signaling, thus 
reducing HPA axis activity. Most importantly, EB and G-1 treatment alter the expression of 
RGSz1 protein isoforms in the PVN, which is consistent with the hypothesis that RGSz1 
post-translational modifications, especially SUMOylation, have a significant functional 
impact on RGSz1 activity and regulation of Gαz signaling in the PVN. Further studies are 
needed to test this hypothesis and determine the mechanisms by which GPER1 signaling 
increases SUMOylation. In addition, the present results demonstrate for the first time that 
peripheral delivery of the selective GPER1 agonist G-1 produces desensitization of 5-
HT1AR signaling. Peripheral delivery is significant for potential translation to preclinical 
and clinical studies, as peripheral injections are more feasible than intra-PVN delivery. 
Moreover, G-1 produced a more robust response than EB and would be less likely to 
produce off-target effects based on receptor selectivity. Our results provide evidence that 
targeting GPER1 and RGSz1 may provide a selective mechanism for the acceleration of 
SSRI therapeutic effects.
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RGSz1 protein in the rat brain. Immunoblot detection of RGSz1 expression in the cytosol (c) 
and membrane (m) fractions of the cortex (CTX), hippocampus (HPC), hypothalamus 
(HTH), and midbrain (MB) using affinity-purified anti-RGSz1 antibody.
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Subcellular distribution of RGSz1 protein in subcellular fractions from discontinuous 
iodixanol gradient centrifugation prepared with rat cortex. Representative immunoblot is 
shown in (A). Graphical representations show the colocalization of RGSz1 with plasma 
membrane marker, Na+/K+ATPase (B); early endosome marker EEA1 (C); and ER marker 
calreticulin (D). Data are expressed as % of peak across fractions, and represent the average 
of three experiments.
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Distribution of RGSz1 protein in sucrose gradient fractions of Triton X-100 treated cortex 
homogenates. (A) A representative immunoblot is shown. Fractions containing the DRM 
were identified by the DRM marker flotillin. Total: Triton X-100 treatment without sucrose 
gradient centrifugation. Graphical representations show the colocalization of RGSz1 with 
flotillin (B and C). Data are expressed as % of peak across fractions, and represent the 
average of three experiments.
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Post-translational modifications of RGSz1. (A) Rat RGSz1 primary amino acid sequence. 
Predicted glycosylation sites are underlined and bolded; predicted SUMOylation site is 
bolded; predicted phosphorylation sites are shaded in gray. (B) RGSz1 immunoblot of 
glycoprotein isolated from cortical membrane fraction. Input: sample before isolation. FT: 
column flow-through. WGA: glycoproteins eluted from wheat germ agglutinin column. (C) 
RGSz1 immunoblot of isolated glycoprotein eluted from column by boiling in SDS-PAGE 
sample buffer. CE: control eluate (WGA column without protein added). CFT: control flow-
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through. (D) Immunoprecipitation (IP) of SUMO-1 and immunoblot detection of RGSz1 in 
cytosol and membrane fractions of cortex. Input: sample before IP. IgG: mouse 
immunoglobin G control. IB: immunoblot. (E) IP of phosphorylated RGSz1 in cytosol and 
membrane fractions of cortex. IgG: rabbit immunoglobin G control. (F) IP of RGSz1 and 
immunoblot detection of SUMO2/3 in cytosol and membrane fractions of cortex. IgG: rabbit 
immunoglobin G control.
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(A) Representative immunoblot of cytosolic RGSz1 from the PVN of rats treated with 
10µg/kg EB or 5mg/kg G-1 (left panel), or challenged with saline or (+)8-OH-DPAT (right 
panel), with β-actin as loading control. Effect of treatment (B) and challenge (C) is 
quantified and combined from three separate immunoblots. (D) Immunoblot comparison of 
RGSz1 high molecular weight bands in the membrane fractions of the PVN and CTX. (E) 
Representative immunoblot of RGSz1 from the membrane fraction of PVN of rats treated 
with 10 µk/kg EB or 5mg/kg G-1 (left panel), or challenged with saline or (+)8-OH-DPAT 
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(right panel), with β-actin as loading control. Effect of treatment (F) or (+)8-OH-DPAT 
challenge (G) is quantified and combined from three separate immunoblots. Bands were 
analyzed densitometrically (integrated optical density, IOD). Each band was normalized to 
β-actin and expressed as percent of control (vehicle or saline). Data are expressed as mean ± 
SEM (n = 4). Note that the 40 and 45kD RGSz1 bands did not appear to resolve into two 
separate bands as seen on the blots prepared with tissue from the subcellular fractionation 
preparations seen in Figure 2. The single band was quantified and labeled as a 40kD band 
although likely represents both the 40 and 45kD RGSz1 isoform. Probing for β actin was 
done on the same immunoblots as RGSz1 and matched to the correct lanes. (*) Significantly 
different from vehicle control; (#) significantly different from EB, p <.05 by Student-
Newman-Keuls post hoc test.
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Effects of 10µg/kg EB, 2.5mg/kg G-1, or 5mg/kg G-1 treatment for 2 days on plasma OT 
(A) and ACTH (B) levels in response to saline or (+)8-OH-DPAT challenge in OVX rats. 
The data are presented as the mean ± SEM (n = 7–8). (*)Significantly different from saline-
challenged group with same treatment, p <.0001; (#)significantly different from (+)8-OH-
DPAT-challenged vehicle group, p <.005 by Student-Newman-Keuls post hoc test.
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Summary of RGSz1 isoform characterization. ↑: increased expression after treatment. ↓: 
decreased expression after treatment. X: no change in expression after treatment. Bands that 
were unmeasured in the PVN are left unmarked.
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